Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide for repairing cartilage and/or treating osteoarthritis

A technology for osteoarthritis and cartilage, applied in the field of peptides and drugs containing the peptides, can solve the problems of difficulty in inducing activity, limited clinical application of BMP-2, difficulty in maintaining therapeutic concentration, etc., and achieve improved efficacy in vivo Duration, promotion of chondrocyte proliferation, and stability improvement effects

Active Publication Date: 2017-05-31
LINK HEALTH GRP
View PDF3 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] BMP-2 is an acidic polypeptide. Its ability to induce bone marrow mesenchymal stem cells to differentiate into osteoblasts is the strongest in the BMP superfamily, but its half-life is relatively short, and the therapeutic concentration is difficult to maintain. There are many target cells, so its inducing activity is difficult to be fully exerted, which has caused great limitations to the clinical application of BMP-2
Most of the BMP-2 drugs currently under research are recombinant BMP-2. As mentioned above, this type of protein has poor stability and short half-life. Therefore, it is urgent to develop a new type of drug to overcome the defects of recombinant BMP-2.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide for repairing cartilage and/or treating osteoarthritis
  • Peptide for repairing cartilage and/or treating osteoarthritis
  • Peptide for repairing cartilage and/or treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The solid-phase synthesis of embodiment 1 BM23 peptide

[0038] BM23 peptide (SEQ ID NO: 1, in which amino acids 1, 7 and 23 use D-glutamine, homoarginine and amidated leucine respectively) commissioned by Shanghai Aobo Biotechnology Co., Ltd. The company adopts conventional solid-phase process synthesis, and the purity of the synthesized peptide is >98%, see figure 1 .

Embodiment 2

[0039] Example 2 Isolation and cultivation of mesenchymal stem cells (BMSCs)

[0040] Three 8-week-old SD rats were killed by dislocation and sterilized with 70% ethanol for 5 minutes. The layers of the abdominal wall are then cut with scissors, the incision is drawn to the femur, and the muscles on the femur are carefully separated.

[0041] Cut off the middle of the femur, draw low-sugar DMEM culture solution (containing 1 mL / L heparin) with a syringe and repeatedly flush the bone marrow cavity to flush out the bone marrow.

[0042] The bone marrow fluid was flushed repeatedly with a syringe, passed through No. 7 and No. 4 needles in turn to make a single-cell suspension.

[0043] The single cell suspension was centrifuged (1500r / min, 10 minutes), and the supernatant was discarded. Add DMEM-F12 complete medium containing 10% FBS to 10 7 The density of each / mL was inoculated in a culture flask, placed at 37°C, 5% CO 2cultured in an incubator.

[0044] Cells were purified...

Embodiment 3

[0048] Example 3 The effect of BM23 peptide on the differentiation of mesenchymal stem cells in vitro

[0049] chondrogenic induction

[0050] The BM23 peptide was dissolved in phosphate buffered saline (PBS).

[0051] The cells were resuspended in complete chondrogenic medium (purchased from Guangzhou Saiye Biotechnology Co., Ltd., product number: RASMX-90011) containing different concentrations of BM23 peptide (0.1, 0.3 and 1 μM), so that the concentration of BMSCs was 5.0× per ml. 10 5 cells. In addition, PBS was used as a negative control, and 1 μM human insulin growth factor (IGF-1, purchased from Beijing Sino Biological Technology Co., Ltd.) was used as a positive control.

[0052] The treated BMSCs were incubated at 37°C and 5% CO2 saturated humidity. Change the medium every 2-3 days and add 0.5 mL of fresh complete chondrogenic medium to each tube.

[0053] Generally, the samples can be collected after 28 days of continuous induction, and the cartilage balls can b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a peptide (called BM23 peptide) which comprises 23 amino acids. The peptide derives from a BMP-2 amino acid sequence and is formed by mutation and modification. Compared with BMP-2, the peptide has remarkably improved stability and in-vivo effect duration, has activity for promoting differentiation of mesenchymal stem cells into cartilage cells and promoting cartilage cell proliferation, and can be used for repairing cartilage and / or treating osteoarthritis.

Description

technical field [0001] The present invention generally relates to the field of peptides, and more specifically, the present invention relates to peptides for repairing cartilage and / or treating osteoarthritis and medicaments comprising said peptides. Background technique [0002] Osteoarthritis (OA) is a common joint disease, manifested as joint pain and stiffness, and cartilage damage is the main cause of osteoarthritis. Primary disease occurs frequently after middle age, and women are more than men, and the prevalence rate of 40-year-old crowd is 10%-17%, 50% over 60 years old, and up to 80% in 75-year-old crowd. The disease has a certain rate of disability. With the aging population, osteoarthritis will become an important issue affecting people's quality of life, and the market demand for osteoarthritis drugs will continue to expand. [0003] At present, clinically, the therapeutic drugs for osteoarthritis are divided into specific therapeutic drugs and non-specific th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/51A61K38/18A61P19/02A61P19/08A61P29/00
CPCC07K14/51A61K38/00A61P19/02C07K2319/00A61K9/0019A61K47/36A61P19/04A61K38/1875
Inventor 宋燕许元生卢肖宇
Owner LINK HEALTH GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com